Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amy E McKee

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Expert Opinion on Therapeutic Targets|September 20, 2006
Targeting caspase 8 to reduce the formation of metastases in neuroblastomaAmy E McKee, Carol J Thiele
The New England Journal of Medicine|April 12, 2018
Breakthrough-Therapy Designation - An FDA PerspectiveJacqueline Corrigan-Curay, Amy E McKee, Peter Stein
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2009
On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biologyCarol J Thiele, Zhijie Li, Amy E McKee
Pediatric Blood & Cancer|May 31, 2019
Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunitiesAmy Barone, Denise Casey, Amy E McKee, et al.
Cancer|May 13, 2017
Regulatory considerations on endpoints in ovarian cancer drug developmentSanjeeve Balasubramaniam, Geoffrey S Kim, Amy E McKee, et al.
The Oncologist|March 19, 2010
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncologyAmy E McKee, Ann T Farrell, Richard Pazdur, et al.
Experimental Biology and Medicine (Maywood, N.J.)|November 7, 2017
The FDA Oncology Center of Excellence and precision medicineKirsten B Goldberg, Gideon M Blumenthal, Amy E McKee, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Complexity of Delivering Precision Medicine: Opportunities and ChallengesAndrew A Davis, Amy E McKee, Warren A Kibbe, et al.
Journal of Clinical Pharmacology|September 19, 2017
How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?Amy E McKee, André O Markon, Kirk M Chan-Tack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2016
FDA's Approach to Regulating BiosimilarsSteven J Lemery, M Stacey Ricci, Patricia Keegan, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Expert Opinion on Therapeutic Targets|September 20, 2006
Targeting caspase 8 to reduce the formation of metastases in neuroblastomaAmy E McKee, Carol J Thiele
The New England Journal of Medicine|April 12, 2018
Breakthrough-Therapy Designation - An FDA PerspectiveJacqueline Corrigan-Curay, Amy E McKee, Peter Stein
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2009
On Trk--the TrkB signal transduction pathway is an increasingly important target in cancer biologyCarol J Thiele, Zhijie Li, Amy E McKee
Pediatric Blood & Cancer|May 31, 2019
Cancer drugs approved for use in children: Impact of legislative initiatives and future opportunitiesAmy Barone, Denise Casey, Amy E McKee, et al.
Cancer|May 13, 2017
Regulatory considerations on endpoints in ovarian cancer drug developmentSanjeeve Balasubramaniam, Geoffrey S Kim, Amy E McKee, et al.
The Oncologist|March 19, 2010
The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncologyAmy E McKee, Ann T Farrell, Richard Pazdur, et al.
Experimental Biology and Medicine (Maywood, N.J.)|November 7, 2017
The FDA Oncology Center of Excellence and precision medicineKirsten B Goldberg, Gideon M Blumenthal, Amy E McKee, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Complexity of Delivering Precision Medicine: Opportunities and ChallengesAndrew A Davis, Amy E McKee, Warren A Kibbe, et al.
Journal of Clinical Pharmacology|September 19, 2017
How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?Amy E McKee, André O Markon, Kirk M Chan-Tack, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 31, 2016
FDA's Approach to Regulating BiosimilarsSteven J Lemery, M Stacey Ricci, Patricia Keegan, et al.
Pageof 4